223 related articles for article (PubMed ID: 29405696)
21. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses.
Rojek JM; Pasqual G; Sanchez AB; Nguyen NT; de la Torre JC; Kunz S
J Virol; 2010 Jan; 84(1):573-84. PubMed ID: 19846507
[TBL] [Abstract][Full Text] [Related]
22. Cells expressing the RING finger Z protein are resistant to arenavirus infection.
Cornu TI; Feldmann H; de la Torre JC
J Virol; 2004 Mar; 78(6):2979-83. PubMed ID: 14990716
[TBL] [Abstract][Full Text] [Related]
23. Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies.
Emonet SE; Urata S; de la Torre JC
Virology; 2011 Mar; 411(2):416-25. PubMed ID: 21324503
[TBL] [Abstract][Full Text] [Related]
24. A Highly Conserved Leucine in Mammarenavirus Matrix Z Protein Is Required for Z Interaction with the Virus L Polymerase and Z Stability in Cells Harboring an Active Viral Ribonucleoprotein.
Iwasaki M; de la Torre JC
J Virol; 2018 Jun; 92(11):. PubMed ID: 29593035
[TBL] [Abstract][Full Text] [Related]
25. Novel drug discovery approaches for treating arenavirus infections.
Pasquato A; Kunz S
Expert Opin Drug Discov; 2016; 11(4):383-93. PubMed ID: 26882218
[TBL] [Abstract][Full Text] [Related]
26. RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus.
Sánchez AB; Perez M; Cornu T; de la Torre JC
J Virol; 2005 Sep; 79(17):11071-81. PubMed ID: 16103158
[TBL] [Abstract][Full Text] [Related]
27. The PI3K/Akt pathway contributes to arenavirus budding.
Urata S; Ngo N; de la Torre JC
J Virol; 2012 Apr; 86(8):4578-85. PubMed ID: 22345463
[TBL] [Abstract][Full Text] [Related]
28. [Arenavirus research and antiviral candidate].
Tani H; Shuzo U
Uirusu; 2018; 68(1):51-62. PubMed ID: 31105135
[TBL] [Abstract][Full Text] [Related]
29. Ribavirin can be mutagenic for arenaviruses.
Moreno H; Gallego I; Sevilla N; de la Torre JC; Domingo E; Martín V
J Virol; 2011 Jul; 85(14):7246-55. PubMed ID: 21561907
[TBL] [Abstract][Full Text] [Related]
30. A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
Cubitt B; Ortiz-Riano E; Cheng BY; Kim YJ; Yeh CD; Chen CZ; Southall NOE; Zheng W; Martinez-Sobrido L; de la Torre JC
Antiviral Res; 2020 Jan; 173():104667. PubMed ID: 31786250
[TBL] [Abstract][Full Text] [Related]
31. Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.
Iwasaki M; Ng CT; Cubitt B; de la Torre JC
J Virol; 2016 Nov; 90(22):10102-10112. PubMed ID: 27581982
[TBL] [Abstract][Full Text] [Related]
32. The C-terminal region of lymphocytic choriomeningitis virus nucleoprotein contains distinct and segregable functional domains involved in NP-Z interaction and counteraction of the type I interferon response.
Ortiz-Riaño E; Cheng BY; de la Torre JC; Martínez-Sobrido L
J Virol; 2011 Dec; 85(24):13038-48. PubMed ID: 21976642
[TBL] [Abstract][Full Text] [Related]
33. Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions.
Moreno H; Grande-Pérez A; Domingo E; Martín V
Viruses; 2012 Nov; 4(11):2786-805. PubMed ID: 23202505
[TBL] [Abstract][Full Text] [Related]
34. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies.
Perez M; Craven RC; de la Torre JC
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12978-83. PubMed ID: 14563923
[TBL] [Abstract][Full Text] [Related]
35. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses.
Lee AM; Rojek JM; Spiropoulou CF; Gundersen AT; Jin W; Shaginian A; York J; Nunberg JH; Boger DL; Oldstone MB; Kunz S
J Biol Chem; 2008 Jul; 283(27):18734-42. PubMed ID: 18474596
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs.
Herring S; Oda JM; Wagoner J; Kirchmeier D; O'Connor A; Nelson EA; Huang Q; Liang Y; DeWald LE; Johansen LM; Glass PJ; Olinger GG; Ianevski A; Aittokallio T; Paine MF; Fink SL; White JM; Polyak SJ
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468464
[TBL] [Abstract][Full Text] [Related]
37. Screening and identification of Lassa virus endonuclease-targeting inhibitors from a fragment-based drug discovery library.
Lan X; Zhang Y; Jia X; Dong S; Liu Y; Zhang M; Guo J; Cao J; Guo Y; Xiao G; Wang W
Antiviral Res; 2022 Jan; 197():105230. PubMed ID: 34965446
[TBL] [Abstract][Full Text] [Related]
38. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.
Martinez-Sobrido L; de la Torre JC
Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328
[TBL] [Abstract][Full Text] [Related]
39. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform.
Welch SR; Spengler JR; Genzer SC; Chatterjee P; Flint M; Bergeron É; Montgomery JM; Nichol ST; Albariño CG; Spiropoulou CF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34203149
[TBL] [Abstract][Full Text] [Related]
40. Targeting of arenavirus RNA synthesis by a carboxamide-derivatized aromatic disulfide with virucidal activity.
Sepúlveda CS; García CC; Levingston Macleod JM; López N; Damonte EB
PLoS One; 2013; 8(11):e81251. PubMed ID: 24278404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
